BTV News Alert: InMed Advances a Rare Cannabinoid that Could Treat Skin & Ocular Diseases
InMed Pharmaceuticals is a biopharmaceutical company. They specialize in the discovery and development of novel, cannabinoid-based therapeutics for th …
InMed is the first to advance a rare cannabinoid to human clinical trials
InMed Pharmaceuticals is a biopharmaceutical company. They specialize in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.
InMed is a leader in the therapeutic development of cannabinol (CBN). Cannabinol is a rare cannabinoid with the potential to treat skin and ocular diseases. They are also the first to advance a cannabinol therapeutic product into human clinical trials. "CBN is distinctly different from THC and CBD. It acts differently in the human body making specific advantages when treating different diseases", says President & CEO Eric Adams. Inmed will be establishing the safety profile of CBN for use in humans.
Further, InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. One proprietary technology is its bioinformatics platform. This uses a computer-based drug candidate selection process to reach high-probability conclusions from massive, publicly available databases together with an internal library of cannabinoid drug information.
InMed is also developing a robust, high-yield, microbial-based biosynthesis process. This is designed to enable the manufacturing of the multitude of cannabinoids (100+) found from natural sources.
As a result of these enabling, proprietary technologies, InMed has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs. These are currently at various stages of preclinical development.
Products in Development
INM-755 is their lead product in development for the treatment of epidermolysis bullosa (“EB”), which is a severe genetic skin disorder.
INM-085 is in development for the treatment of glaucoma, the second leading cause of blindness in the developed world.
INM-405 is a product in development for the treatment of localized pain, specifically orofacial pain.
For more information on InMed Pharmaceuticals Inc. (IN:TSX, IMLFF:OTCQX) please fill out the form below.
Latest Articles
Hot Companies
You might also like
BTV Showcases Contango Ore, Critical Elements Lithium, Dryden Gold, FireFox Gold, Kirkland Lake, Klondike Gold, and Selkirk Mines
This week, BTV - Business Television we feature growth-focused mining companies advancing major projects across North America and Europe. From emerging producers and strategic combinations to high-grade exploration and critical mineral development, this episode highlights the next wave of opportunity in the resource sector, including:
Selkirk Copper: A Yukon restart positioned to deliver new Canadian copper supply by 2028
A 50,000-metre drill program began last summer to expand understanding of the resource and guide updated mine design. The goal is to define a 12–15 year mine life while refreshing permits and engineering.
